Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025 well beyond the next key milestones for both therapeutic candidates.
Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), executed a sale of 269,719 shares in the company on January 4, 2024, according to a recent SEC Filing.
WALTHAM, Mass., Jan. 05, 2024 Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically.